Compare DNUT & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNUT | ZURA |
|---|---|---|
| Founded | 1937 | 2022 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Food Chains | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 541.3M | 435.0M |
| IPO Year | 2021 | N/A |
| Metric | DNUT | ZURA |
|---|---|---|
| Price | $3.84 | $6.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $4.78 | ★ $11.78 |
| AVG Volume (30 Days) | ★ 1.7M | 466.6K |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.17% | N/A |
| EPS Growth | ★ 108.70 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,665,397,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.58 | $0.99 |
| 52 Week High | $6.51 | $7.19 |
| Indicator | DNUT | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 69.16 | 60.81 |
| Support Level | $3.00 | $5.62 |
| Resistance Level | $3.89 | $6.76 |
| Average True Range (ATR) | 0.15 | 0.47 |
| MACD | 0.09 | 0.02 |
| Stochastic Oscillator | 76.40 | 68.75 |
Krispy Kreme Inc is a sweet treat brand company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in-your-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing e-commerce and delivery business. The company conducts its business through the following three reported segments: U.S., which includes all operations in the United States; International, which includes operations in the U.K., Ireland, Australia, New Zealand, Canada, Japan, and Mexico; and Market Development, which includes franchise operations across the globe. It derives maximum revenue from the U.S. segment.
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.